Abstract: AXL-specific antibodies and uses therefor are described, including monoclonal and single domain antibodies. Such antibodies bind to cell surface expressed human AXL at an epitope in an immunoglobulin-like (IgL) domain of the AXL ectodomain. The antibody may be used in an antibody-drug conjugate (ADC), for example in the treatment, detection or staging of cancer. The antibody may be biparatopic.

Abstract: Antibodies that bind to AXL protein and variants thereof are described herein. AXL exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the MAbs of the invention provide a diagnostic composition for the treatment and management of cancer.

Abstract: The present invention relates to human CCR8 (hCCR8) binders, wherein the hCCR8 binder is cross-reactive with a non-human primate CCR8. Such binders are particularly useful for the depletion of intra-tumoural regulatory T-cells and immunotherapy in general.

Abstract: This disclosure provides an antibody or antigen-binding fragment or derivative thereof that specifically binds to CD123. Also provided are polynucleotides encoding the antibody or antigen-binding fragment or derivative thereof and vectors and host cell comprising said polynucleotides. This disclosure further provides methods for producing and/or using an antibody or antigen-binding fragment or derivative thereof that specifically binds to CD123.

Abstract: A method of reducing IL-4 and/or IL-13 levels in the lung of a mammal with elevated levels thereof, includes the step of administering to the mammal an effective amount of a ?c receptor blocker capable of blocking the binding of all three of IL-3, IL-5 and GM-CSF to the ?c common chain to thereby reduce the IL-4 and/or IL-13 levels.

Abstract: Provided herein are anti-CD30 antibody-drug conjugates and methods of using the same to modulate the immune response in a subject.

Abstract: The present application provides anti-CD137 constructs that bind to CD137 (e.g., anti-CD137 monoclonal antibodies and multispecific antibodies), nucleic acid molecules encoding an amino acid sequence of the anti-CD137 constructs, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of preparing the anti-CD137 constructs, pharmaceutical compositions containing the anti-CD137 constructs, and methods of using the anti-CD137 constructs or compositions.

Abstract: Provided herein are antibodies, and antigen-binding fragments thereof that specifically bind glucocorticoid-induced tumor necrosis factor receptor (GITR), compositions comprising the antibodies or antigen-binding fragments thereof, and methods of using the same, including, e.g., methods of treatment using the same.

Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.

Abstract: Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.

Abstract: The present disclosure relates to an engineered antibody that co-engages a cell type-selective (or specific) antigen (guide) and a signaling receptor (effector) on a target cell. In some instances, the engineered antibody is capable of modulating a signaling pathway on a target cell. In other embodiments, an engineered antibody of the present disclosure is administered to a subject for the treatment of a disease or condition.

Abstract: Disclosed herein are epithelial cell adhesion molecule (EpCAM)-specific binding polypeptides. These binding polypeptides may be incorporated into chimeric antigen receptors (CARs). Also disclosed herein are methods of using these binding polypeptides and/or CARs for the treatment of, for example, a cancer.

Abstract: The present invention relates to a conjugate or a fusion protein comprising: (a) an anti-TLT-1 (triggering receptors expressed on myeloid cells like transcript-1) antibody, and (b) a payload, wherein the anti-TLT-1 antibody and the payload are covalently linked together, and the payload is an anti-neoplastic molecule, an anti-mitotic molecule, a transcription or translation inhibitor, or a cytokine. The anti-TLT-1 antibody directs and targets the conjugate or the fusion protein to activated platelets in a tumor microenvironment (TME) through binding of the antibody to TLT-1, a membrane protein receptor that is only present on activated platelets. As a result, the targeted cytotoxic molecules or therapeutic proteins effectively inhibit the tumor growth. The present invention also relates to specific single domain antibodies (sdAbs) or sdAb based heavy chain-only antibody (HcAb) against TREM (triggering receptors expressed on myeloid cells) like transcript-1 (TLT-1).

Abstract: Methods for using anti-LIV1 antibodies, including drug conjugated anti-LIV1 antibodies, to inhibit proliferation of a LIV-1-expressing cell, as well as for the treatment of one or more diseases or disorders associated with LIV-1-expressing cells (e.g., a LIV-1-associated breast cancer), are provided.

Abstract: An antibody or antigen-binding fragment specifically binding to HER2, a multi-specific antigen binding molecule, a chimeric antigen receptor, an immune effector cell, a nucleic acid fragment, a vector, a host cell, a pharmaceutical composition, a kit, a preparation method, and an application thereof in treatment of tumors or cancers and detection of HER2, which is of great significance for the development of HER2 antibody therapeutic drugs and detection reagents.

Abstract: The invention provides methods and compositions for treating cancer and for enhancing immune function in an individual having cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane.

Abstract: The present disclosure provides an expression vector, comprising: a first expression cassette having a first transcriptional regulatory element and an immunoglobulin heavy chain-coding region operatively linked to the first transcriptional regulatory element; a second expression cassette having a second transcriptional regulatory element and an immunoglobulin light chain-coding region operatively linked to the second transcriptional regulatory element; and a third expression cassette having a third transcriptional regulatory element and an immunoglobulin J chain-coding region operatively linked to the third transcriptional regulatory element. The present disclosure further relates to the host cell comprising the expression vector and the use thereof.

Abstract: The present disclosure relates to a single domain antibody that specifically binds to the epitope in the catalytic domain of carbonic anhydrase IX (CA-IX). The single domain antibody has a dissociation constant (KD) of 1×10?7 or lower for a monomeric form of human CA-IX and/or a dimeric form of human CA-IX.

Abstract: It is demonstrated herein that inhibitors of immune checkpoints and CHI3L1 are synergistic. Accordingly, described herein are methods and compositions relating to combinatorial therapies for cancer, e.g., comprising an inhibitor of CHI3L1; and an inhibitor of an immune checkpoint protein. In some embodiments, the CHI3L1 inhibitor can be an antibody or antibody reagent as described herein.

Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact.

Abstract: The present invention relates to the treatment of IgE-mediated disease. The inventors hypothesized that formation of immune complexes between Omalizumab and IgE might be responsible for some of the adverse reactions observed in highly atopic patients (i.e. patients with a history of anaphylaxis and/or high IgE titers). Immune complexes can induce inflammation through activation of Fc gamma receptors (Fc?Rs) and/or the complement cascade. They identified that Omalizumab:hIgE immune complexes activate human Fc?Rs in vitro. Moreover, similarly to some of the reported side effects observed in human, Omalizumab:hIgE immune complexes can induce anaphylaxis when injected in mice expressing human Fc?Rs. Using publicly available omalizumab VH and VL sequences, they cloned and produced two mutant versions of omalizumab in which residues in the Fc portion of the Ab were mutated.

Abstract: This disclosure provides multispecific and multivalent antigen binding proteins. In one aspect, the disclosure provides a multispecific antigen binding protein, comprising a first antigen binding site comprising a first VHH that specifically binds to a first epitope; and a second antigen binding site that specifically binds to a second epitope.

Abstract: An isolated anti-CD47 antibody or fragment thereof has the ability of binding CD47 and competing with the binding of SIRPa to CD47, and comprises a heavy chain variable region comprising heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3; and a light chain variable region comprising light chain complementarity determining regions LCDR1, LCDR2, and LCDR3. A method for treating a disorder in which CD47 is overexpressed or upregulated in a subject, comprises using an isolated anti-CD47 antibody or fragment thereof having the ability of binding CD47 and competing with the binding of SIRPa to CD47. A bispecific antibody comprises a first antigen binding moiety that binds to human GPC3 (hGPC3); and a second antigen binding moiety that binds to human CD47 (hCD47).

Abstract: An object of the present invention is to stably and efficiently provide an oxidized cellulose having excellent fibrillatability. The above object can be achieved by a method of producing an oxidized cellulose, which contains an oxide of a cellulose raw material by a hypochlorous acid or a salt thereof, is substantially free of N-oxyl compounds, and has a degree of polymerization of 600 or less, the method including a step of obtaining an oxidized cellulose by oxidizing a cellulose raw material using a hypochlorous acid or a salt thereof, wherein viscosity of a slurry of the cellulose raw material having the same concentration as when the oxidation is performed is in a range of 1,000 Pa·s or less at 30° C. or 40° C.

Abstract: The present invention relates to a dextrin with improved turbidity, and a method for producing same.

Abstract: Provided are supramolecular polypseudorotaxane hydrogel compositions and 3-D structures capable of reversible 3-D structural deformation which include (a) a solvent; (b) an at least partially linear polymer, where the polymer further comprises groups capable of covalent crosslinking between the polymers; (ii) at least one first macrocyclic ring which forms a pseudorotaxane with a polymer in the polymer network; and (iii) at least one second macrocyclic ring that does not form the pseudorotaxane. The hydrogel composition has a viscosity which allows for 3-D printing of the hydrogel to form a 3-D structure, and a storage (elastic) modulus after crosslinking that allows for the 3-D structure to undergo reversible 3-D structural deformation upon change of solvent conditions. Also provided are methods of manufacturing the compositions and 3-D structures.

Abstract: Fungal crosslinked structures, fungal crosslinking systems, and methods for crosslinking a fungal material. The crosslinked fungal material described herein comprises a variety of crosslinkers, crosslinking sites, and various combinations of crosslinks, each forming unique structures. The crosslinked fungal material comprises at least one crosslinking compound attached to a bonding site. The fungal crosslinking system includes a preparation unit, an impregnating unit, a crosslinking unit and a rinsing unit. The preparation unit may partially deacetylate chitin within the fungal material and within chitin nanowhiskers. The impregnating unit impregnates the fungal material with chitin nanowhiskers. The crosslinking unit is configured to crosslink the fungal material and chitin nanowhiskers via genipin to create a composite material. The rinsing unit rinses and removes unreacted genipin material thereby rendering a crosslinked composite material.

Abstract: The present disclosure provides a method for manufacturing an auto-crosslinked hyaluronic acid gel, comprising conducting auto-crosslinking reaction of a colloid containing hyaluronic acid continuously at low temperature in an acidic environment, and treating the reaction product with steam at high temperature to obtain the auto-crosslinked hyaluronic acid gel with high viscosity.

Abstract: A process or apparatus for producing polyethylene with improved film thinning and handleability involves polymerizing high-pressure ethylene using an autoclave-type reactor in the presence of a polymerization initiator. The reaction zone of the reactor has at least two different temperature sections; the polymerization initiator and the ethylene are supplied to the upstream temperature section in the reaction zone and the ethylene is polymerized to generate polyethylene; unreacted ethylene and the polyethylene generated at the upstream temperature section in the reactor flow into the downstream temperature section in communication with the upstream temperature section, so that additional polyethylene is generated at the downstream temperature section. A difference (?T [° C.]) between a temperature (T1 [° C.]) of the temperature section positioned upstream and a temperature (T2 [° C.

Abstract: A composite polyimide separator and a preparation method thereof, and a secondary battery are described. The preparation method of the composite polyimide separator comprises: providing a porous polyamic acid film; subjecting a diamine aqueous solution and an acyl chloride organic solution to an interfacial polymerization reaction on a surface of the porous polyamic acid film to obtain a composite polyamic acid separator; and placing the composite polyamic acid separator in vapor of an imidization reagent for imidization treatment to obtain the composite polyimide separator. In the present application, by controlling the parameters of the interfacial polymerization reaction, a composite polyamic acid separator with a dense surface, a loose bottom, and an adjustable surface pore size can be obtained.

Abstract: Provided is a photocurable resin composition including a reactive compound, and a photopolymerization initiator. A cured product of the photocurable resin composition has two or more glass transition points including a TgA and a TgB. The TgA is less than 25° C., and the TgB is 25° C. or more. An elongation at break in accordance with ASTM D638 of the cured product of the photocurable resin composition is 130% or more, and a breaking strength in accordance with ASTM D638 of the cured product of the photocurable resin composition is 3 MPa or more.

Abstract: Provided herein is technology relating to polymerization and producing polymers and particularly, but not exclusively, to methods, systems, and compositions for producing articles using three-dimensional printing and for improving control of polymerization using a polymerization photoinhibitor having fast back reaction kinetics such as hexaarylbiimidazole compounds and bridged hexaarylbiimidazole compounds.

Abstract: A supported metallocene catalyst includes a carrier and a metallocene component. The carrier includes an inorganic oxide particle and an alkyl aluminoxane material. The inorganic oxide particle includes at least one inorganic oxide compound selected from the group consisting of an oxide of Group 3A and an oxide of Group 4A. The alkyl aluminoxane material includes an alkyl aluminoxane compound and an alkyl aluminum compound that is present in amount ranging from greater than 0.01 wt % to less than 14 wt % base on 100 wt % of the alkyl aluminoxane material. The metallocene component is supported on the carrier, and includes one of a metallocene compound containing a metal from Group 3B, a metallocene compound containing a metal from Group 4B, and a combination thereof. A method for preparing the supported metallocene catalyst and a method for preparing polyolefin using the supported metallocene catalyst are also disclosed.

Abstract: To produce an olefin-based polymer having a minor amount of decrease in bulk density due to heat. A solid catalyst component for olefin polymerization containing a titanium atom, a magnesium atom, a halogen atom, and an internal electron donor, and having an envelope E1 calculated by the following Formula (1) in a range of 0.810 to 0.920. E1=LE1/LS1??(1) (In Formula, LE1 is a convex hull perimeter of the solid catalyst component for olefin polymerization obtained from an image of the solid catalyst component for olefin polymerization captured with a scanning electron microscope, and LS1 is an actual perimeter of the solid catalyst component for olefin polymerization obtained from the image of the solid catalyst component for olefin polymerization captured with the scanning electron microscope.

Abstract: Disclosed herein are ethylene-based polymers generally characterized by a melt index of less than 1 g/10 min, a density from 0.93 to 0.965 g/cm3, a CY-a parameter at 190° C. of less than 0.2, an average number of short chain branches per 1000 total carbon atoms of the polymer in a molecular weight range of 400,000 to 600,000 g/mol that is greater than that in a molecular weight range of 40,000 to 60,000 g/mol, and an average number of long chain branches per 1000 total carbon atoms of the polymer in a molecular weight range of 400,000 to 600,000 g/mol that is greater than that in a molecular weight range of 4,000,000 to 6,000,000 g/mol.

Abstract: To provide a 4-methyl-1-pentene polymer being excellent in storage stability when dissolved in a solvent and solubility, and being excellent in at least one of heat resistance, and a coating appearance when a coating film is stretched, for example, when such a film is bended or used in a flexible application. A 4-methyl-1-pentene polymer (A) being a copolymer of 4-methyl-1-pentene and at least one selected from linear ?-olefins having 6 to 20 carbon atoms, the 4-methyl-1-pentene polymer (A) satisfying the following requirements (I) and (II): (I) an endotherm end temperature (TmE) in a melting (endothermic) curve measured by DSC is 230° C. or lower; and (II) an exotherm start temperature (TcS) in a crystallization (exothermic) curve measured by DSC is 210° C. or lower.

Abstract: The present invention relates to resin particles including a residue unit represented by the following general formula (1) and having a volume average particle diameter equal to or more than 5 ?m and equal to or less than 2008 ?m, and a method for producing thereof. Fruthermore the present invention relates to a fluororesin comprising a residue unit represented by a general formula (1) and having a weight average molecular weight Mw in a range of 5×104 to 3×105, and a yellow index of a heat-melted molded product (thickness 3 mm) after 24 h at 280° C. of equal to or less than 6, and a method for producing thereof. In the formula (1), Rf1, Rf2, Rf3, and Rf4 are each independently one of the groups consisting of a fluorine atom, a linear perfluoroalkyl group having 1 to 7 carbon atoms, a branched perfluoroalkyl group having 3 to 7 carbon atoms, or a cyclic perfluoroalkyl group having 3 to 7 carbon atoms. The perfluoroalkyl group may have an ethereal oxygen atom.

Abstract: Catalyst systems and methods for making and using the same. A method of methylating a catalyst composition while substantially normalizing the entiomeric distribution is provided. The method includes slurrying the organometallic compound in dimethoxyethane (DME), and adding a solution of RMgBr in DME, wherein R is a methyl group or a benzyl group, and wherein the RMgBr is greater than about 2.3 equivalents relative to the organometallic compound. After the addition of the RMgBr, the slurry is mixed for at least about four hours. An alkylated organometallic is isolated, wherein the methylated species has a meso/rac ratio that is between about 0.9 and about 1.2.

Abstract: The present invention relates to aqueous polymer dispersion of voided polymer particles and to a process for preparing such aqueous polymer dispersions. The present invention also relates to polymer particles, in particular powders of said polymer particles, which are obtained by drying a polymer dispersion. Further aspects of the present invention relate to the use of such voided polymer particles and the polymer dispersions as opacifiers and to paints containing such aqueous polymer dispersions. The voided polymer particles comprise: i) an alkali swellable polymer core of polymerized ethylenically unsaturated monomers M(i) comprising polymerized acid monomers M(i.ac) in an amount sufficient for allowing the polymer core to swell at a pH of at least pH 7.

Abstract: Described herein are conductive fluorinated elastomeric materials and methods of making and using the same. The conductive fluorinated elastomeric materials include a fluorinated polymeric matrix and one or more high aspect-ratio fillers, wherein a surface resistance of the elastomeric material is 15 ohm/square or less and/or a bulk conductivity of the elastomeric material is 0.7 Ohm-cm or less. Also described herein are liquid fluorinated elastomeric compositions, including a fluorinated polymer, one or more high aspect-ratio fillers, and a solvent. Further described herein are molded products including the conductive fluorinated elastomeric materials as described herein and wearable devices including the molded products.

Abstract: A polyacrylate random copolymer is synthesized from acrylic acid (AA), butyl acrylate (BA), methyl methacrylate (MMA), and 2-ethylhexyl acrylate (EHA). The copolymer is suitable for workup into a water emulsion and may be applied to a surface in liquid form, quickly drying to yield a peelable protective barrier film.

Abstract: Disclosed herein are a method for producing materials having at least one carbamate functionality, carbamate-functional materials obtained from the process, coating compositions including said carbamate-functional materials, and a process for at least partially coating a substrate with the coating compositions. The method disclosed herein reduces unwanted transesterification which can occur as a side reaction by using a tertiary alkyl carbamate in combination with a tin catalyst and thus results in increased yields and purity of the carbamate-functional materials.

Abstract: Polyolefins having the same or different functional groups covalently bound to the polyolefin, such as polyolefins having hindered phenol groups bound thereto, can be prepared by from a maleic anhydride modified polyolefin, with or without a coupling agent, and a hindered phenol reagent under heat, e.g., by heating the components to at least about 170° C., such as by reactive extrusion. A polyolefin having hindered phenol groups can be added to the components as a stabilizer prior to or during reacting the components together under heat.

Abstract: The present disclosure relates to liquid compositions including a (meth)acrylic polymer, a (meth)acrylic monomer, and a maturation agent selected from a metal oxide or a metal hydroxide. The (meth)acrylic polymer can contain a monomer carrying a carboxylic acid function and/or the (meth)acrylic monomer can carrying a carboxylic acid function. The liquid compositions can also contain a dynamic viscosity between 10 mPa·s and 10 000 mPa·s at 25° C.

Abstract: Provided is an oxygen-curable silicone composition that cures at room temperature, the reaction being triggered by oxygen in the atmosphere, without requiring heat or UV irradiation at the time of use, and exhibits good mechanical strength after curing. A composition including (A) an organopolysiloxane (1) (R1 represents an alkyl group or the like but has at least one acryloyloxy group or the like in the molecule, R2 represents an oxygen atom or the like, and m and n represent numbers that satisfy 1?m+n 1,000.), (B) a silicone resin including (a) a unit of formula (2), (b) an R13SiO1/2 unit, and (c) an SiO4/2 unit, the molar ratio of [(a)+(b)]/(c) being 0.4-1.2, and the silicone resin having 0.005 mol/100 g or more Si-OH groups (R1 and R2 are the same as above. R3 represents an acryloyloxyalkyl group or the like, p represents 0-10, and 1 represents a number that satisfies 1-3.), and (C) an organoborane complex (3) (R4-R6 represent hydrocarbon groups.).

Abstract: A polymer comprising a repeating structure of formula (I) wherein Ar in each occurrence is an arylene or heteroarylene group; p is at least 2; one of Y1 and Y2 is CR1 wherein R1 is H or a substituent; and the other of Y1 and Y2 is N. The polymer may be formed by reaction of monomers containing reactive groups which react to form an imine. The polymer may be used as a thermally conductive polymer, e.g. a thermally conductive layer of an electronic device.

Abstract: The present disclosure relates to a polyurethane foam composition, comprising (A) a polyol component, comprising one or more polyols selected from the group consisting of a polyester polyol, a polyether polyol, and the combination thereof, wherein the one or more polyols have an average hydroxyl group functionality of from 3 to 7 and an average hydroxyl group number of from 300 to 1000 mg KOH/g; and (B) an isocyanate component, comprising one or more isocyanate compounds; wherein in either or both of the (A) polyol component and the (B) isocyanate component, the polyurethane foam composition further comprises one or more flame retardants in an amount of no more than 15 percent by weight based on the total weight of the polyurethane foam composition, and, one or more blowing agents; and wherein the NCO/OH ratio of the isocyanate component to the polyol component is within the range of from 0.5:1 to 5:1.

Abstract: A polyurethane foam may include a base polyol component, a phosphorous polyol component, an expandable graphite, and melamine. The polyurethane foam may have a VO rating based on a UL94 flame retardancy test performed at a polyurethane foam thickness of 3.5 mm and a polyurethane foam density of 380 kg/m3.

Abstract: Methods, compositions, and kits for adhering polymers and other materials to another material, and in particular to bone or bone-like structures or surfaces. A composition of matter includes a urethane dimethacrylate-methyl methacrylate copolymer with a plurality of first polymer regions based on urethane dimethacrylate and a plurality of second polymer regions based on methyl methacrylate. The method includes placing an orthopedic joint implant having an attachment surface in a joint space, applying a first non-urethane-containing precursor, a second urethane-containing precursor, and a initiator to the attachment surface; contacting the first and second precursors and the initiator with the joint surface; and copolymerizing the first and second precursors and forming an adhesive copolymer and attaching the implant to the joint.